ferric citrate | 2338-05-8

• 物质功能分类: 有机原料 - 有机金属盐
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ferric citrate
• 英文别名: iron(III) citrate；iron citrate；Nephoxil；2-hydroxypropane-1,2,3-tricarboxylate;iron(3+)
• CAS: 2338-05-8
• 化学式: C₆H₅O₇*Fe
• 分子量: 244.948
• InChiKey: NPFOYSMITVOQOS-UHFFFAOYSA-K

物化性质

• 密度：
  1.906[at 20℃]
• LogP：
  1 at 20℃
• 物理描述：
  Ferric ammonium citrate is a yellowish brown to red solid with a faint odor of ammonia. It is soluble in water. The primary hazard is the threat to the environment. Immediate steps should be taken to limit its spread to the environment. It is used in medicine, in making blueprints, and as a feed additive.
• 分解：
  When heated to decomposition it emits acrid smoke and irritating fumes.
• 稳定性/保质期：
  稳定，光线敏感。

计算性质

• 辛醇/水分配系数(LogP)：
  -5.26
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  141
• 氢给体数：
  1
• 氢受体数：
  7

ADMET

毒理性

• 在妊娠和哺乳期间的影响

使用期间的总结：铁是母乳中的正常成分。各种形态的铁的研究表明，外源性给药后，母乳中的铁含量并没有显著增加。无需特别注意。持温巴氏杀菌会减少牛奶中铁的浓度约6.5%。 有关哺乳期间使用铁的更多信息，请参阅关于铁盐的单篇论文。 对哺乳婴儿的影响：截至修订日期，没有找到相关的已发布信息。 对泌乳和母乳的影响：截至修订日期，没有找到相关的已发布信息。

◉ Summary of Use during Lactation:Iron is a normal component of human milk. Studies on various forms of iron indicate that breastmilk levels are not increased greatly after exogenous administration. No special precautions are necessary. Holder pasteurization reduces the concentration of iron in milk by about 6.5%. For additional information on iron use during breastfeeding, see the monograph on Iron Salts. ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)

安全信息

• WGK Germany：
  3
• 海关编码：
  2918150000
• 储存条件：
  室温且干燥

SDS

---

Section 1. Chemical Product and Company Identification
Catalog
Ferric Citrate
Common Name/ YY1591, F1028
Number(s).
Trade Name
CAS# 2338-05-8(anhydrous CAS
no.)
Manufacturer
Commercial Name(s)
Ferric Citrate

---

Section 4. First Aid Measures
Eye Contact Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water
for at least 15 minutes. Cold water may be used. Get medical attention if irritation occurs.
Skin Contact Wash with soap and water. Cover the irritated skin with an emollient. Get medical attention if irritation
develops. Cold water may be used.
Serious Skin Contact Not available.
Inhalation If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Get medical attention.
Serious Inhalation Not available.
Ingestion Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to
an unconscious person. If large quantities of this material are swallowed, call a physician immediately.
Loosen tight clothing such as a collar, tie, belt or waistband.
Serious Ingestion Not available.

---

Section 5. Fire and Explosion Data
Flammability of the Product May be combustible at high temperature.
Auto-Ignition Temperature Not available.
Not available.
Flash Points
Flammable Limits Not available.
Products of Combustion These products are carbon oxides (CO, CO2). Some metallic oxides.
Fire Hazards in Presence of Slightly flammable to flammable in presence of heat.
Various Substances
Slightly explosive in presence of open flames and sparks.
Explosion Hazards in
Non-explosive in presence of shocks.
Presence of Various
Substances
SMALL FIRE: Use DRY chemical powder.
Fire Fighting Media
LARGE FIRE: Use water spray, fog or foam. Do not use water jet.
and Instructions
Special Remarks on As with most organic solids, fire is possible at elevated temperatures
Fire Hazards
Special Remarks on Explosion Fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential
dust explosion hazard.
Hazards

---

Section 6. Accidental Release Measures
Small Spill Use appropriate tools to put the spilled solid in a convenient waste disposal container. Finish cleaning by
spreading water on the contaminated surface and dispose of according to local and regional authority
requirements.
Large Spill Use a shovel to put the material into a convenient waste disposal container. Finish cleaning by spreading
water on the contaminated surface and allow to evacuate through the sanitary system.

---

Section 7. Handling and Storage
Keep away from heat. Keep away from sources of ignition. Ground all equipment containing material. Do
Precautions
not ingest. Do not breathe dust. Wear suitable protective clothing. If ingested, seek medical advice
immediately and show the container or the label. Keep away from incompatibles such as oxidizing agents.
Storage Keep container tightly closed. Keep container in a cool, well-ventilated area. Sensitive to light. Store in
light-resistant containers.
Ferric Citrate

---

Section 8. Exposure Controls/Personal Protection
Engineering Controls Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels
below recommended exposure limits. If user operations generate dust, fume or mist, use ventilation to keep
exposure to airborne contaminants below the exposure limit.
Personal Protection Safety glasses. Lab coat. Dust respirator. Be sure to use an approved/certified respirator or equivalent.
Gloves.
Personal Protection in Case of Splash goggles. Full suit. Dust respirator. Boots. Gloves. A self contained breathing apparatus should be
a Large Spill used to avoid inhalation of the product. Suggested protective clothing might not be sufficient; consult a
specialist BEFORE handling this product.
TWA: 1 (mg(Fe)/m3) from ACGIH (TLV) [United States]
Exposure Limits
TWA: 1 (mg(Fe)/m3) from NIOSH [United States]
TWA: 1 STEL: 2 (mg(Fe)/m3) [Canada]
TWA: 1 STEL: 2 (mg((Fe)/m3) [United Kingdom (UK)]
Consult local authorities for acceptable exposure limits.

---

Section 9. Physical and Chemical Properties
Physical state and appearance Solid. (Powdered solid.) Odor Not available.
Taste Not available.
Molecular Weight 244.95 g/mole + xH20
pale-brown or grayish-brown
Color
Not available.
pH (1% soln/water)
Boiling Point Not available.
Not available.
Melting Point
Critical Temperature Not available.
Specific Gravity Not available.
Vapor Pressure Not applicable.
Vapor Density Not available.
Not available.
Volatility
Odor Threshold Not available.
Not available.
Water/Oil Dist. Coeff.
Ionicity (in Water) Not available.
Dispersion Properties See solubility in water.
Solubility Easily soluble in hot water.
Soluble in cold water.
Slowly, but completely soluble in cold water.
Readily soluble in hot water.
Insoluble in alcohol.

---

Section 10. Stability and Reactivity Data
Stability The product is stable.
Instability Temperature Not available.
Conditions of Instability Excess heat, incompatible materials, dust generation, light
Incompatibility with various Reactive with oxidizing agents.
substances
Not available.
Corrosivity
Special Remarks on Sensitive to light.
Reactivity
Ferric Citrate
Not available.
Special Remarks on
Corrosivity
Polymerization Will not occur.

---

Section 11. Toxicological Information
Routes of Entry Inhalation. Ingestion.
Acute oral toxicity (LD50): 1487 mg/kg [Rat].
Toxicity to Animals
Acute dermal toxicity (LD50): 2000 mg/kg [Rabbit].
Chronic Effects on Humans May cause damage to the following organs: liver.
Slightly hazardous in case of skin contact (irritant), of ingestion, of inhalation.
Other Toxic Effects on
Humans
Special Remarks on Not available.
Toxicity to Animals
Special Remarks on Not available.
Chronic Effects on Humans
Special Remarks on other Acute Potential Health Effects:
Toxic Effects on Humans Skin: May cause skin irritation.
Eyes: May cause eye irritation.
Inhalation: This material may produce dust. May cause upper respiratory tract (nose, throat) irritation.
Symptoms may include coughing, sore throat, labored breathing and chest pain. Breathing small amounts
of this material during normal handling is not likely to cause harmful effects.
Ingestion: Swallowing small amounts during normal handling is not likely to cause harmful effects.
Swallowing large amounts of iron may be harmful and may cause gastrointestinal upset (nausea, vomiting,
diarrhea) and may also affect the liver. Furthermore, pink urine is a strong indicator of iron poisoning.
Chronic Potential Health Effects:
Ingestion: Prolonged or repeated ingestion of large quantities may cause liver damage.

---

Section 12. Ecological Information
Ecotoxicity Not available.
BOD5 and COD Not available.
Products of Biodegradation Possibly hazardous short term degradation products are not likely. However, long term degradation
products may arise.
Toxicity of the Products The product itself and its products of degradation are not toxic.
of Biodegradation
Not available.
Special Remarks on the
Products of Biodegradation

---

Section 13. Disposal Considerations
Waste must be disposed of in accordance with federal, state and local environmental
Waste Disposal
control regulations.

---

Section 14. Transport Information
DOT Classification Not a DOT controlled material (United States).
Not applicable.
Identification
Special Provisions for Not applicable.
Transport
Ferric Citrate
DOT (Pictograms)

---

Section 15. Other Regulatory Information and Pictograms
Rhode Island RTK hazardous substances: Listed as Iron soluble salts
Federal and State
Pennsylvania RTK: Listed as Iron salts
Regulations
Minnesota: Listed as Iron soluble salts
California Director's List of Hazardous Substances: Listed as Iron soluble salts
TSCA 8(b) inventory: Ferric Citrate
California California prop. 65: This product contains the following ingredients for which the State of California has
Proposition 65 found to cause cancer which would require a warning under the statute: No products were found.
Warnings
California prop. 65: This product contains the following ingredients for which the State of California has
found to cause birth defects which would require a warning under the statute: No products were found.
Other Regulations OSHA: Hazardous by definition of Hazard Communication Standard (29 CFR 1910.1200).
EINECS: This product is on the European Inventory of Existing Commercial Chemical Substances (EINECS
No. 219-045-4).
Canada: Listed on Canadian Domestic Substance List (DSL).
China: Not listed on National Inventory.
Japan: Listed on National Inventory (ENCS).
Korea: Not listed on National Inventory (KECI).
Philippines: Listed on National Inventory (PICCS).
Australia: Listed on AICS.
WHMIS (Canada) Not controlled under WHMIS (Canada).
Other Classifications
DSCL (EEC) This product is not classified Not applicable.
according to the EU regulations.
Health Hazard
HMIS (U.S.A.) 1 National Fire Protection
1 Flammability
1 Association (U.S.A.)
Fire Hazard
1 0 Reactivity
Health
Reactivity
0
Specific hazard
Personal Protection
E
WHMIS (Canada)
(Pictograms)
DSCL (Europe)
(Pictograms)
TDG (Canada)
(Pictograms)
ADR (Europe)
(Pictograms)
Protective Equipment
Gloves.
Ferric Citrate
Lab coat.
Dust respirator. Be sure to use an
approved/certified respirator or
equivalent.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

鉴别试验

柠檬酸盐试验（IT-13）和铁盐试验（IT-19）呈阳性。

含量分析

准确称取试样约1g，放入磨口玻塞烧瓶中，加入5ml盐酸和25ml水，加热溶解后冷却。随后加入4g碘化钾，密封后在暗室放置15min，再加100ml水，用0.1mol/L硫代硫酸钠溶液滴定游离的碘，以淀粉试液（TS-235）为指示剂。同时进行空白试验。每毫升0.1mol/L硫代硫酸钠溶液相当于5.585mg铁。

毒性

口服1～2mg/kg剂量会出现中毒症状；而10mg/kg则导致死亡。皮下注射铁剂可能会引发不良反应。

使用限量

GB 14880—94（mg/kg）：谷类及其制品，150～290；饮料60～120；乳制品、婴幼儿配方食品，360～600；食盐、夹心糖，3600～7200。

化学性质

红褐色透明小薄片或褐色粉末。水溶液呈酸性，在光和热的作用下会逐渐还原为柠檬酸亚铁。在水中溶解缓慢，热水比冷水更易溶解，不溶于乙醇。

用途

作为营养增补剂（用于强化铁质），适用于饼干、改质奶粉和小麦粉等产品。印度将其添加至食盐中。

生产方法

将氨水加入硫酸铁溶液中，生成氢氧化铁沉淀；过滤、水洗直至无硫酸反应后，再加柠檬酸并加热至60℃以下使沉淀溶解；最后将滤液浓缩成糖浆状，在玻璃板上涂布形成小片状，微温干燥而成。

类别

腐蚀物质

可燃性危险特性

可燃。火场排出含铁的辛辣刺激烟雾。

储运特性

库房低温、通风、干燥；与强氧化剂分开存放。

灭火剂

水、二氧化碳、干粉、砂土。

反应信息

• 作为反应物：
  描述：

  ferric citrate 在 apoferritin 作用下， 以 not given 为溶剂， 生成 ferroin
  参考文献：
  名称：

  Photochemical Mineralization of Europium, Titanium, and Iron Oxyhydroxide Nanoparticles in the Ferritin Protein Cage

  摘要：

  The Fe storage protein ferritin was used as a size-constrained reaction vessel for the photoreduction and reoxidation of complexed Eu, Fe, and Ti precursors for the formation of oxyhydroxide nanoparticles. The resultant materials were characterized by dynamic light scattering, gel electrophoresis, UV-vis spectroscopy, and transmission electron microscopy. The photoreduction and reoxidation process is inspired by biological sequestration mechanisms observed in some marine siderophore systems.

  DOI：

  10.1021/ic701740q
• 作为产物：
  描述：

  柠檬酸 在 sodium hydroxide 、 iron(III) chloride hexahydrate 作用下， 以 水 为溶剂， 反应 1.5h， 以85%的产率得到ferric citrate
  参考文献：
  名称：

  [EN] PHARMACEUTICAL GRADE FERRIC CITRATE AND METHOD FOR ITS PRODUCTION
  [FR] CITRATE FERRIQUE DE QUALITÉ PHARMACEUTIQUE ET SON PROCÉDÉ DE PRODUCTION

  摘要：

  柠檬酸铁提供的BET活性表面积范围为1-15 m2/gm。还提供了一种制备药用级柠檬酸铁的方法。

  公开号：

  WO2015110968A1
• 作为试剂：
  描述：

  那可汀 在 ferric citrate 、 间氯过氧苯甲酸 作用下， 生成 盐酸诺格考平
  参考文献：
  名称：

  Stereochemical Elucidation of the Reaction Products of .ALPHA.-Narcotine with Ethyl Chloroformate.

  摘要：

  α-那可丁（1）在二氯甲烷中与乙基氯甲酸酯回流反应，得到了六个产物，这些产物通过制备型高效液相色谱（HPLC）进行了分离。它们的立体化学和结构被阐明。这一反应最初生成氯代氨基甲酸酯，随后依次生成相应的甲醇。此外，在HPLC色谱图中发现的N-去甲基-N-羧乙基那可丁（3），通过与合成3直接比较得以确认；该化合物曾在我们之前的质谱研究中造成困难。

  DOI：

  10.1248/cpb.43.1995

文献信息

• Room Temperature Palladium-Catalyzed Decarboxylative Acyl/Aroylation using [Fe(III)(EDTA)(η²-O₂)]³⁻as Oxidant at Biological pH
  作者：Sugandha Sharma、Imran A. Khan、Anil K. Saxena

  DOI：10.1002/adsc.201201085

  日期：2013.3.11

  The purple‐coloured iron peroxo complex [Fe(III)EDTA(η2‐O2)]3− as a novel reagent system for Pd‐catalyzed decarboxylative ortho‐acylation of acetanilides with α‐oxocarboxylic acids at room temperature in aqueous media has been realized. This reaction provides an effective access to ortho‐acylacetanilides under mild conditions.

  紫色着色铁过氧络合物的[Fe（III）EDTA（η 2 -O 2）] 3-作为Pd催化脱羧的新型试剂系统邻在含水介质中在室温下用α-氧代羧酸乙酰苯胺的酰化具有被实现。该反应可在温和条件下有效地获得邻酰基乙酰基苯胺。
• Characterization of multiferroic PbFe_0.5 Nb_0.5 O₃ and PbFe_0.5 Ta_0.5 O₃ ceramics derived from citrate polymeric precursors
  作者：Irena Gruszka、Antoni Kania、Ewa Talik、Magdalena Szubka、Seweryn Miga、Joanna Klimontko、Jan Suchanicz

  DOI：10.1111/jace.15998

  日期：2019.3

  Ceramics of the perovskite multiferroics PbFe0.5Nb0.5O3 (PFN) and PbFe0.5Ta0.5O3 (PFT) were synthesized from new citrate polymeric precursors. X‐ray tests pointed to trace amounts of the pyrochlore phase. SEM studies revealed the heterogeneous grain size distribution for PFN and the homogeneous one for PFT. Dielectric studies pointed to one diffuse T‐C phase transition at 378 K for PFN and two diffuse

  由新型柠檬酸盐聚合物前驱体合成了钙钛矿多铁化合物PbFe 0.5 Nb 0.5 O 3（PFN）和PbFe 0.5 Ta 0.5 O 3（PFT）的陶瓷。X射线测试指出了痕量的烧绿石相。SEM研究表明，PFN的晶粒尺寸分布不均匀，PFT的晶粒尺寸分布均匀。介电研究指出，PFN在378 K处发生一个扩散T-C相变，PFT分别在200和235 K处发生两个扩散M-T和T-C相变。PFN的X射线光电子能谱研究表明，所有离子均以一种价态存在，但是Pb 2+具有两个化学位移。大多数PFT离子的两个价态似乎与无定形晶界相的较高体积分数有关。两种化合物的电子能带隙约为2.8 eV。对于PFN，分别在156和10 K处以及在PFT在145和15 K处，观察到两个磁跃迁，即从顺磁性到反铁磁相，然后到自旋玻璃相。
• [EN] PROCESS FOR THE PREPARATION OF PHARMACEUTICAL GRADE FERRIC CITRATE<br/>[FR] PROCÉDÉ DE PRÉPARATION DE CITRATE FERRIQUE DE QUALITÉ PHARMACEUTIQUE
  申请人：LUPIN LTD

  公开号：WO2017021921A1

  公开（公告）日：2017-02-09

  The objective of the present invention is a one-pot process for the preparation of pharmaceutical grade ferric citrate comprises of preparing a ferric hydroxide slurry followed by treatment with a citrate ion source to yield pharmaceutical grade ferric citrate.

  本发明的目标是一种一锅法制备药用级柠檬酸亚铁的过程，包括制备亚铁羟糊浆，然后用柠檬酸盐离子源处理，以得到药用级柠檬酸亚铁。
• Method for the Synthesis of Ferric Oraganic Compounds
  申请人：Biophore India Pharmaceuticals Pvt. Ltd.

  公开号：US20190047934A1

  公开（公告）日：2019-02-14

  The present invention relates to an improved method for the synthesis of Ferric Citrate and also to provide an amorphous form of Ferric Citrate having an active surface area less than 14 sq.m/g.

  本发明涉及一种改进的合成柠檬酸亚铁的方法，同时提供一种具有活性表面积小于14平方米/克的柠檬酸亚铁的非晶形式。
• Manufacturing Method of Ferric Citrate
  申请人：Tokuyama Corporation

  公开号：US20200299317A1

  公开（公告）日：2020-09-24

  A method of manufacturing is provided for obtaining ferric citrate by a simple drying operation, the ferric citrate having a high purity, a high specific surface area, and a reduced water-soluble organic solvent content. The method of manufacturing ferric citrate, comprises a wet material of ferric citrate, containing the ferric citrate and a water-soluble organic solvent and having a water-soluble organic solvent content within the range of more than 0.3% by mass to 30.0% by mass or less, dried by bringing a gas containing water into contact.

  提供了一种制造方法，通过简单的干燥操作获得柠檬酸亚铁，该柠檬酸亚铁具有高纯度、高比表面积和降低的水溶性有机溶剂含量。制造柠檬酸亚铁的方法包括柠檬酸亚铁的湿料，其中含有柠檬酸亚铁和水溶性有机溶剂，并且水溶性有机溶剂含量在质量百分比超过0.3%至不超过30.0%的范围内，通过使含水气体接触干燥。